Completed PHASE3 INTERVENTIONAL 2-arm NCT01856309

Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003 (SIRROUND-LTE)

A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (Sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T)

Sponsor: GlaxoSmithKline

Conditions Arthritis, Rheumatoid

Interventions Placebo Sirukumab 100 mg Sirukumab 50 mg

Updated 14 times since 2017 Last updated: Apr 12, 2019 Started: Aug 7, 2013 Primary completion: Apr 30, 2018 Completion: Apr 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01856309, this PHASE3 trial focuses on Arthritis, Rheumatoid and remains completed. Sponsored by GlaxoSmithKline, it has been updated 14 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

14 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3

▶ Show 9 earlier versions

Jun 2019 — Jan 2021 [monthly]

Completed PHASE3
Oct 2018 — Jun 2019 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Aug 2018 — Oct 2018 [monthly]

Active Not Recruiting PHASE3
Jun 2018 — Aug 2018 [monthly]

Active Not Recruiting PHASE3
Dec 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE3
Aug 2017 — Dec 2017 [monthly]

Active Not Recruiting PHASE3
Mar 2017 — Aug 2017 [monthly]

Active Not Recruiting PHASE3
Feb 2017 — Mar 2017 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Janssen Research & Development, LLC

Data source: Janssen Research & Development, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Albuquerque, United States , Alytus, Lithuania , Austin, United States , Aventura, United States , Ayauta, Japan , Barakaldo, Spain , Barnaul, Russia , Beckley, United States , Belgrade, Serbia and 186 more locations